Prolonged low doses of oral etoposide may be effective in individual patients with advanced lymphoproliferative disorders refractory to aggressive chemotherapy.
Caruso
R
R
Alesiani
F
F
Latagliata
R
R
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016879:Salvage Therapy
D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide